Does Positive KT-621 Atopic Dermatitis Data Change The Bull Case For Kymera Therapeutics (KYMR)? [Yahoo! Finance]
Kymera Therapeutics, Inc. (KYMR)
Company Research
Source: Yahoo! Finance
meaningful improvements in adults with moderate-to-severe atopic dermatitis over 28 days, with a favorable safety profile. The depth of STAT6 degradation in both skin and blood, alongside broad reductions in Type 2 inflammatory biomarkers, highlights KT-621's potential to bring biologics-like efficacy to an oral therapy in atopic dermatitis. We'll now consider how KT-621's early atopic dermatitis efficacy and biomarker profile could influence Kymera's broader investment narrative and pipeline outlook. Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution. Kymera Therapeutics Investment Narrative Recap To own Kymera, you need to believe that targeted protein degradation can translate into real-world drugs, and that KT-621 can anchor a broader immune-inflammatory franchise before cash resources tighten. The positive BroADen Phase 1b atopic dermatitis data strengthens the KT-621 story and supports th
Show less
Read more
Impact Snapshot
Event Time:
KYMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KYMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KYMR alerts
High impacting Kymera Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KYMR
News
- Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual MeetingGlobeNewswire
- Kymera Therapeutics (KYMR) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.MarketBeat
- Kymera Trials IRF5 And STAT6 Degraders As Market Weighs Long Term Upside [Yahoo! Finance]Yahoo! Finance
- Kymera Therapeutics, Inc. (KYMR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
KYMR
Earnings
- 2/26/26 - Miss
KYMR
Sec Filings
- 4/1/26 - Form 4
- 4/1/26 - Form 4
- 4/1/26 - Form 144
- KYMR's page on the SEC website